Albert Bourla on scientific renaissance
From Pfizer CEO doubles down on 2024 guidance, talks Seagen buy · · Yahoo Finance
“I think that going forward we are going to see in the Life Sciences particularly significant advancements not only in biology but also in technology AI being one of them that will allow us to deliver meaningful solutions to patients for diseases that they didn't have a solution before oncology it is clearly one of our very big bets but the same will happen in many other areas”
On , Albert Bourla, Chairman of the Board & Chief Executive Officer at Pfizer Inc, spoke about scientific renaissance during Pfizer CEO doubles down on 2024 guidance, talks Seagen buy on Yahoo Finance.
About Albert Bourla
Albert Bourla, chairman and CEO of Pfizer, said on the company’s first-quarter 2026 earnings call that the company’s strong performance reflected “disciplined execution” and that new and acquired products grew 22% in the quarter. He stated that Pfizer does not plan a large merger in the near term, describing the next few years as a time to “execute on AI transformation” rather than pursue a mega-merger. Bourla also highlighted recent patent settlements for Vyndamax, which he said give the company confidence it will enter a period of high single-digit revenue growth starting in 2029. He noted that Pfizer invested nearly $80 billion in recent years to acquire molecules and pipelines to offset upcoming patent losses. In multiple interviews, Bourla discussed the rise of China’s pharmaceutical sector, arguing that the U.S. should focus on improving its own innovation rather than trying to slow China’s progress. He described China’s scientific capabilities as having a “meteoric rise” and said that by the end of the decade, eight of the world’s top ten universities based on peer-reviewed publications were Chinese. Bourla expressed optimism about artificial intelligence, calling it “transformative” and predicting it will contribute to a “scientific renaissance” in medicine. He also commented on U.S. health policy, saying he was encouraged by recent statements from Trump administration officials about modernizing the FDA and accelerating drug development, though he said he had not yet seen practical effects. Bourla described his increased time in Washington as necessary because health care has become “extremely politicized” and because governments are major customers for Pfizer.